Learn more about Oncotype DX test for DCIS and Early-Stage Breast Cancer
Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smarter at every stage, our Oncotype IQ diagnostic tests and services portfolio delivers clinically relevant genomic intelligence that reveals the individual biology of a patient's tumor. This additional genomic insight helps physicians optimize treatment decisions for breast, colon, prostate and lung cancers.
Oncotype DX has been used to guide treatment decisions for more than 1 million cancer patients worldwide.
"With millions of cancer patients around the world, it is critical to be able to individualize care. Oncotype DX tests have paved the way for precision medicine by providing personalized information based on the unique biology of every cancer, and by enabling confident, individualized treatment decisions. Genomic testing has become a mainstream component of cancer care, and patients are seeing the benefits through improved outcomes."